Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HPN | P05981 | 1/20 | 0.46 |
| ▸ | NQO2 | P16083 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.43 |
| ▸ | BACE1 | P56817 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SRC | P12931 | 1/20 | 0.43 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.42 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.42 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.42 |
| ▸ | FLT3 | P36888 | 2/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.42 |
| ▸ | KIT | P10721 | 1/20 | 0.42 |
| ▸ | BCR | P11274 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | SMAD3 | P84022 | 1/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30920730 | 0.90 | NQO2 (0.48) | SMN1; SMN2HPNNQO2KDM4ACACNA1H | |
| SCHEMBL19964287 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2HPNKDM4ARAB9ACACNA1H | |
| SCHEMBL19964551 | 0.86 | SMN1; SMN2 (0.55) | SMN1; SMN2HPNKDM4ARAB9ACACNA1H | |
| SCHEMBL25677972 | 0.84 | KDM4A (0.54) | SMN1; SMN2KDM4ARAB9ACACNA1HCACNA1B | |
| SCHEMBL30469092 | 0.84 | KDM4A (0.54) | SMN1; SMN2KDM4ARAB9ACACNA1HCACNA1B | |
| SCHEMBL19964549 | 0.82 | SMN1; SMN2 (0.51) | SMN1; SMN2HPNKDM4ARAB9ACACNA1H | |
| SCHEMBL30130020 | 0.82 | SMN1; SMN2 (0.48) | SMN1; SMN2HPNKDM4ARAB9ACACNA1H | |
| SCHEMBL30130002 | 0.81 | MAOA (0.60) | SMN1; SMN2RAB9AFLT3PDGFRBNPC1 | |
| SCHEMBL23478663 | 0.80 | SMN1; SMN2 (0.48) | SMN1; SMN2KDM4ACACNA1HCACNA1BCACNA1C | |
| SCHEMBL30920299 | 0.80 | SMN1; SMN2 (0.51) | SMN1; SMN2HPNNQO2KDM4ARAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240124399-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | METACEN THERAPEUTICS (KR) | 2024-04-18 | — | — | US | disclosed |
| EP-4353710-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | Metacen Therapeutics (KR) | 2024-04-17 | — | — | EP | disclosed |
| WO-2022260491-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | 주식회사 메타센테라퓨틱스 | 2022-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240124399-A1 | NOVEL INDOLE DERIVATIVE, AND USE THEREOF FOR TREATING DISEASES RELATED TO ADVANCED GLYCATION END PRODUCTS | AGER, IDO1, IDO2 | SMN1; SMN2 4446/4885HPN 1473/4885NQO2 990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.